Diminished response to treatment with anti-EGFR monoclonal antibodies is found in KRAS-mutant or BRAF-mutant colorectal cancer [5–8] but these mutations do not impair response to oxaliplatin- (OxPt) or cisplatin-based chemotherapy [9, 10]. Here, BRAF is linked to colorectal cancer.